These guys have a a buy recommendation from goldman small caps, a PR about better than expected results. These things are huge for a bio tech company. If they get phase 3 clinicals this will become a pricey stock quick
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.